Literature DB >> 15577410

Long-term persistence of primary genotypic resistance after HIV-1 seroconversion.

David Pao1, Ushan Andrady, Janette Clarke, Gillian Dean, Susan Drake, Martin Fisher, Tanya Green, Siva Kumar, Maurice Murphy, Alan Tang, Stephen Taylor, David White, Gillian Underhill, Deenan Pillay, Patricia Cane.   

Abstract

Primary infection with drug-resistant HIV-1 is well documented. We have followed up patients infected with such viruses to determine the stability of resistance-associated mutations. Fourteen patients who experienced primary infection with genotypic evidence of resistance were followed for up to 3 years. Drug resistance-associated mutations persisted over time in most patients studied. In particular, M41L, T69N, K103N, and T215 variants within reverse transcriptase (RT) and multidrug resistance demonstrated little reversion to wild-type virus. By contrast, Y181C and K219Q in RT, occurring alone, disappeared within 25 and 9 months, respectively. Multidrug resistance in 2 patients was found to be stable for up to 18 months, the maximum period studied. We conclude that certain resistance-associated mutations are highly stable and these data support the recommendation that all new HIV diagnoses in areas where primary resistance may occur should undergo genotyping irrespective of whether the date of seroconversion is known.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15577410     DOI: 10.1097/00126334-200412150-00006

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  31 in total

1.  The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.

Authors:  Mian-er Cong; Walid Heneine; J Gerardo García-Lerma
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

2.  Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine.

Authors:  Mark A Micek; Ana Judith Blanco; Ingrid A Beck; Sandra Dross; Laurinda Matunha; Pablo Montoya; Kristy Seidel; Soren Gantt; Eduardo Matediane; Lilia Jamisse; Stephen Gloyd; Lisa M Frenkel
Journal:  Clin Infect Dis       Date:  2010-05-15       Impact factor: 9.079

3.  HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis.

Authors:  Virginie Supervie; J Gerardo García-Lerma; Walid Heneine; Sally Blower
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

4.  Differential persistence of transmitted HIV-1 drug resistance mutation classes.

Authors:  Vivek Jain; Maria C Sucupira; Peter Bacchetti; Wendy Hartogensis; Ricardo S Diaz; Esper G Kallas; Luiz M Janini; Teri Liegler; Christopher D Pilcher; Robert M Grant; Rodrigo Cortes; Steven G Deeks; Frederick M Hecht
Journal:  J Infect Dis       Date:  2011-04-15       Impact factor: 5.226

5.  Low prevalence of transmitted HIV type 1 drug resistance among antiretroviral-naive adults in a rural HIV clinic in Kenya.

Authors:  Amin S Hassan; Shalton M Mwaringa; Clare A Obonyo; Helen M Nabwera; Eduard J Sanders; Tobias F Rinke de Wit; Patricia A Cane; James A Berkley
Journal:  AIDS Res Hum Retroviruses       Date:  2012-09-11       Impact factor: 2.205

6.  Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort.

Authors:  Barbara Bartmeyer; Claudia Kuecherer; Claudia Houareau; Johanna Werning; Kathrin Keeren; Sybille Somogyi; Christian Kollan; Heiko Jessen; Stephan Dupke; Osamah Hamouda
Journal:  PLoS One       Date:  2010-10-07       Impact factor: 3.240

7.  Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda.

Authors:  Guinevere Q Lee; David R Bangsberg; Conrad Muzoora; Yap Boum; Jessica H Oyugi; Nneka Emenyonu; John Bennett; Peter W Hunt; David Knapp; Chanson J Brumme; P Richard Harrigan; Jeffrey N Martin
Journal:  AIDS Res Hum Retroviruses       Date:  2014-07-29       Impact factor: 2.205

8.  Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.

Authors:  Susan J Little; Simon D W Frost; Joseph K Wong; Davey M Smith; Sergei L Kosakovsky Pond; Caroline C Ignacio; Neil T Parkin; Christos J Petropoulos; Douglas D Richman
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

9.  Contribution of recombination to the evolution of human immunodeficiency viruses expressing resistance to antiretroviral treatment.

Authors:  Tamara Nora; Charlotte Charpentier; Olivier Tenaillon; Claire Hoede; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

10.  Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients.

Authors:  Art F Y Poon; Sergei L Kosakovsky Pond; Douglas D Richman; Simon D W Frost
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.